Both tirzepatide (Mounjaro) and semaglutide (Ozempic) have made headlines in recent months for their benefits in broad patient populations. This new analysis compared the two medications in obese/overweight adults with and without type 2 diabetes.

The popular diet prioritizes whole grains, fruits, vegetables, legumes, nuts, seeds and olive oil. Researchers found that it was associated with multiple long-term benefits for patients with a cancer diagnosis. 

“This finding shows great potential to enhance the success of chemotherapy while protecting the heart," one researcher said. 

Grocery stores have started selling more and more plant-based meat alternatives in recent years, and early evidence suggests replacing even some meat with these products may be beneficial. Researchers did note that more studies on this subject are still needed.

Individuals with underlying heart disease may want to avoid energy drinks going forward, according to a new Mayo Clinic analysis.

Teva Pharmaceuticals has officially launched generic liraglutide injections in the United States. Novo Nordisk currently sells liraglutide under the brand name Victoza.

Based on positive results from two different trials, Eli Lilly and Company hopes to secure a new FDA approval for tirzepatide in the months ahead.

“Understanding the sex differences in obesity-related HFpEF is of great importance,” one cardiologist explained. “Obesity and visceral adiposity are key drivers of HFpEF development and progression, and this may be even more amplified in women."